Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

R. Bavalia, R. Abdoellakhan, H.J.M. Brinkman, M.P.A. Brekelmans, E.N. Hamulyak, M. Zuurveld, B.A. Hutten, P.E. Westerweel, R.H. Olie, H. ten Cate, M. Kruip, S. Middeldorp, K. Meijer, M. Coppens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)569-581
Number of pages13
JournalResearch and practice in thrombosis and haemostasis
Volume4
Issue number4
DOIs
Publication statusPublished - 1 May 2020

Keywords

  • apixaban
  • atrial-fibrillation
  • dabigatran
  • emergencies
  • factor xa inhibitors
  • hemorrhage
  • idarucizumab
  • prothrombin complex concentrates
  • reversal
  • rivaroxaban
  • safety
  • thrombin generation
  • vitamin-k antagonists
  • warfarin
  • SAFETY
  • RIVAROXABAN
  • APIXABAN
  • THROMBIN GENERATION
  • VITAMIN-K ANTAGONISTS
  • FACTOR XA INHIBITORS
  • ATRIAL-FIBRILLATION
  • REVERSAL
  • DABIGATRAN
  • WARFARIN
  • factor Xa inhibitors

Cite this